Century Therapeutics Highlights Progress in Immune-Evasive Cell Therapies

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn update from Century Therapeutics ( (IPSC) ) is now available. On January 12, 2026, Century Therapeutics updated an investor slide presentation detailing progress across its cell therapy pipeline and plans to unlock the value of its programs in Type 1 diabetes and autoimmune disease. The company highlighted that CNTY-813 and CNTY-308, both incorporating its Allo-Evasion 5.0 technology for enhanced immune evasion and persistence, are in IND-enabling studies with CNTY-813 targeted for an investigational filing in 2026 and early clinical data expected in 2027, while CNTY-308 is anticipated to enter the clinic in 2026. Century also reported that patient enrollment is ongoing in the Phase 1/2 CARAMEL investigator-sponsored trial of CNTY-101 in autoimmune disease, and said its cash runway extends beyond planned key clinical milestones, underscoring its capacity to advance multiple high-impact programs in parallel and strengthen its position as a leader in immune-evasive allogeneic cell therapies. The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page. Spark’s Take on IPSC Stock According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral. The score is held back primarily by heavy cash burn and ongoing losses despite a reasonably supported balance sheet. Strong technical momentum and positive corporate developments (notably the $135M financing) improve the outlook, but negative earnings/FCF and hard-to-assess valuation with a negative P/E keep the overall score moderate. To see Spark’s full report on IPSC stock, click here. More about Century Therapeutics Century Therapeutics is a cell therapy company developing induced pluripotent stem cell (iPSC)-derived products engineered with its Allo-Evasion immune evasion technology, with a primary focus on Type 1 diabetes and B cell–mediated autoimmune diseases. Its pipeline includes CNTY-813, a beta islet cell therapy for Type 1 diabetes; CNTY-308, an allogeneic αβ T-cell therapy; and CNTY-101, an iNK cell therapy, all designed for outpatient administration and aimed at providing durable, potentially re-dosable treatments for autoimmune disorders. Average Trading Volume: 1,662,428 Technical Sentiment Signal: Buy Current Market Cap: $154.7M Learn more about IPSC stock on TipRanks’ Stock Analysis page.